甲磺酸萘莫司他治疗住院COVID-19患者:结构化叙述性综述
本文对甲磺酸萘莫司他(nafamostat)治疗COVID-19的临床前、药代动力学和临床结局数据进行叙述性综述。体外研究中萘莫司他对SARS-CoV-2的IC50为0.0022 µM(瑞德西韦为1.3 µM),可能通过抑制TMPRSS2阻止病毒进入细胞,并具有抗血栓活性。现有临床报告有限但提示对中重度COVID-19患者可能有获益,需持续招募临床试验以提供更稳健的安全性和有效性数据。
要点
- 萘莫司他在人肺细胞系中对SARS-CoV-2的体外抗病毒效力高(IC50 0.0022 µM)。
- 萘莫司他已在日本和韩国获批用于急性胰腺炎和弥散性血管内凝血等适应症。
- 现有临床报告有限,提示对中重度COVID-19患者可能有潜在获益。
核心结论
- 萘莫司他具有高体外抗SARS-CoV-2活性和抗血栓活性,现有临床报告有限但提示对中重度COVID-19患者可能有潜在获益。
- 需持续招募临床试验以提供萘莫司他治疗COVID-19更稳健的安全性和有效性数据。
研究设计与样本
- 本文为结构化叙述性综述,检索并汇总萘莫司他治疗COVID-19的临床前、药代动力学和临床结局数据。
主要发现
- 人肺细胞系体外研究显示萘莫司他对SARS-CoV-2的IC50为0.0022 µM,瑞德西韦为1.3 µM。
- 萘莫司他抗病毒作用可能通过抑制细胞酶TMPRSS2阻止病毒进入人细胞。
- 萘莫司他具有已知的抗血栓活性,鉴于COVID-19血栓相关后遗症可能具有优势。
- 现有临床报告有限,但提示萘莫司他在中重度COVID-19患者中可能有潜在获益。
关键数值与推荐
- 体外人肺细胞系中萘莫司他对SARS-CoV-2的IC50为0.0022 µM,瑞德西韦为1.3 µM。
临床怎么用
- 萘莫司他仅可连续静脉输注给药,已在日本和韩国获批用于急性胰腺炎和弥散性血管内凝血等适应症。
- 现有临床证据有限,临床使用应优先在正在进行的临床试验框架内进行。
局限性
- 现有临床报告有限,尚缺乏稳健的安全性和有效性数据。
- 需通过正在进行的临床试验进一步验证萘莫司他治疗COVID-19的获益与风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The search for clinically effective antivirals against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is ongoing. Repurposing of drugs licensed for non-coronavirus disease 2019 (COVID-19) indications has been extensively investigated in laboratory models and in clinical studies with mixed results. Nafamostat mesylate (nafamostat) is a drug licensed in Japan and Korea for indications including acute pancreatitis and disseminated intravascular coagulation. It is available only for continuous intravenous infusion. In vitro human lung cell line studies with nafamostat demonstrate high antiviral potency against SARS-CoV-2 (half maximal inhibitory concentration [IC50] of 0.0022 µM [compared to remdesivir 1.3 µM]), ostensibly via inhibition of the cellular enzyme transmembrane protease serine 2 (TMPRSS2) preventing viral entry into human cells. In addition, the established antithrombotic activity is hypothesised to be advantageous given thrombosis-associated sequelae of COVID-19. Clinical reports to date are limited, but indicate a potential benefit of nafamostat in patients with moderate to severe COVID-19. In this review, we will explore the pre-clinical, pharmacokinetic and clinical outcome data presently available for nafamostat as a treatment for COVID-19. The recruitment to ongoing clinical trials is a priority to provide more robust data on the safety and efficacy of nafamostat as a treatment for COVID-19.
引用
- Hernández-Mitre MP, Tong SYC, Denholm JT, et al. Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review. Clin Pharmacokinet. 2022. PMID: 36040613. doi:10.1007/s40262-022-01170-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。